Signal Genetics, Inc. (MGEN)
(Delayed Data from NSDQ)
$2.83 USD
+0.05 (1.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.82 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.83 USD
+0.05 (1.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.82 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q3 revenues increase year over year.
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.
Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up
by Zacks Equity Research
Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales. Recovery in other two segments encouraging.
Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 29.41% and -74.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Signal Genetics, Inc. (MGEN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Jun 18, 2020
by Zacks Equity Research
Companies in the news are: WATT, ARMP, MGEN, CEMI
Signal Genetics, Inc. (MGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -24.00% and -9.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Signal Genetics, Inc. (MGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Jan 31, 2020
by Zacks Equity Research
Companies In The News Are: BGG, INO, MDLZ, MGEN
Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -20.00% and -58.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Signal Genetics, Inc. (MGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 21.62% and 184.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -8.57% and -72.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Signal Genetics, Inc. (MGEN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -6.45% and -69.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 9.38% and -50.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Signal Genetics (MGEN) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Signal Genetics (MGEN) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
2 Biotech Stocks with Month-Long Upward Estimate Revisions
by Zacks Equity Research
Although the biotech sector initially picked up this year, it witnesses a correction since October. However, it is a good idea to select stocks witnessing positive estimate revisions for a month now.
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
by Zacks Equity Research
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks
by Zacks Equity Research
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.